TA
Therapeutic Areas
Scholar Rock Holding Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Apitegromab (SRK-015) | Spinal Muscular Atrophy (SMA) | Phase 3 |
| SRK-181 | Solid Tumors (Anti-PD-1 Resistant) | Phase 1/2 |
| SRK-439 | Obesity / Muscle Atrophy | Preclinical |
Leadership Team at Scholar Rock Holding
JB
Jay Backstrom
President & Chief Executive Officer
TM
Ted Myles
Chief Financial Officer & Head of Business Operations
YC
Yung Chyung
Chief Medical Officer
DH
David Hallal
Chairman of the Board
MQ
Mo Qatanani
Chief Scientific Officer
LW
Luhua Wang
Senior Vice President, Discovery & Translational Sciences
SB
Sasha B. Moghaddam
Senior Vice President, General Counsel
AG
Amy G. W. Lochary
Senior Vice President, Head of Human Resources
MC
Matthew C. Frankel
Senior Vice President, Corporate Development & Strategy
NM
Nagesh Mahanthappa
Board Member